Table 2 Results of prospective randomized trials
From: Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit
Country | Author | Ref | Trial name | Year | Conclusions |
|---|---|---|---|---|---|
Use in respiratory infections | |||||
Switzerland | Christ-Crain | [20] | None | 2006 | PCT level prevented initial antibx use, earlier discontinuation antibx, less overall use |
Switzerland | Briel | [23] | None | 2008 | PCT level prevented initial antibx use, decreased overall antibx exposure and duration |
Swiss/USA | Stolz | [25] | None | 2009 | PCT level allowed earlier discontinuation antibx, decreased total exposure and duration |
Switzerland | Schuetz | [26] | ProHosp | 2009 | adverse outcomes similar, PCT group had fewer adverse events, less total antibx use |
Use in sepsis | |||||
Switzerland | Nobre | [21] | None | 2008 | PCT allowed earlier discontinuation of antibx, decreased overall antibx exposure |
Germany | Schroeder | [22] | None | 2008 | PCT allowed earlier discontinuation of antibx, cost of antibx reduced |
Use in sepsis in the ICU setting | |||||
Germany | Hochreiter | [24] | None | 2009 | PCT allowed earlier discontinuation of antibx, shorter ICU length of stay |
France | Bouadma | [27] | PRORATA | 2010 | PCT allowed earlier discontinuation of antibx, decreased overall antibx exposure |
Netherlands | De Jong | [28] | SAPS | 2013 | No longer recruiting patients, results pending |
Australia | Shehabi | [30] | ProGuard | 2014 | PCT group had 2 less days of antibx but not statistically significant |